Invasive fungal infections, notably candidemia, have been associated with COVID-19. The epidemiology of candidemia has significantly changed during the COVID-19 pandemic. We aim to identify the microbiological profile, resistance rates, and outcomes of COVID-19-associated candidemia (CAC) compared to patients with candidemia not associated with COVID-19. We retrospectively collected data on patients with candidemia admitted to the American University of Beirut Medical Center between 2004 and 2022. We compared the epidemiology of candidemia during and prior to the COVID-19 pandemic. Additionally, we compared the outcomes of critically ill patients with CAC to those with candidemia without COVID-19 from March 2020 till March 2022. Among 245 candidemia episodes, 156 occurred prior to the pandemic and 89 during the pandemic. Of the latter, 39 (43.8%) were CAC, most of which (82%) were reported from intensive care units (ICU). Non-albicans (NAC) spp. were predominant throughout the study period (67.7%). infection was the most common cause of NAC spp. in CAC. had decreased susceptibility rates to fluconazole and caspofungin during the pandemic period (46.1% and 38.4%, respectively). The mortality rate in the overall ICU population during the pandemic was 76.6%, much higher than the previously reported candidemia mortality rate observed in studies involving ICU patients. There was no significant difference in 30-day mortality between CAC and non-CAC (75.0% vs. 78.1%; = 0.76). Performing ophthalmic examination ( = 0.002), CVC removal during the 48 h following the candidemia ( = 0.008) and speciation ( = 0.028) were significantly associated with a lower case-fatality rate. The epidemiology of candidemia has been significantly affected by the COVID-19 pandemic at our center. Rigorous infection control measures and proper antifungal stewardship are essential to combat highly resistant species such as .
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381108 | PMC |
http://dx.doi.org/10.3390/jof9070769 | DOI Listing |
Mycoses
January 2025
Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Background: Infections with fluconazole-resistant Candida parapsilosis have been increasing in Israeli hospitals with unclear implications for patient outcomes.
Objectives: To determine the frequency, mechanisms, molecular epidemiology, and outcomes of azole-resistant C. parapsilosis bloodstream infections in four hospitals in Israel.
J Leukoc Biol
January 2025
Center for Engineering in Medicine and Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA.
In tissues, neutrophils neutralize Candida albicans through phagocytosis and delay C. albicans hyphae growth by deploying neutrophil extracellular traps (NETs). However, in the bloodstream, the dynamic interactions between NETs and C.
View Article and Find Full Text PDFInfect Dis Clin Microbiol
December 2024
Department of Infectious Diseases and Clinical Microbiology, İstanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, İstanbul, Türkiye.
Curr Med Mycol
May 2024
Department of Microbiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029, India.
Curr Med Mycol
May 2024
Department of Microbiology, Sri Ramachandra Medical College & Research Institute, SRIHER, Porur, Chennai 600116, India.
Background And Purpose: is the third most commonly isolated species from candidemia patients admitted to Indian intensive care units. Outbreak of infection and emergence of fluconazole resistance associated with this particular species has been increasingly documented since 2018. Worldwide data has documented that Y132F substitution in the gene is the predominant fluconazole resistance mechanism among .
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!